WINSTON-SALEM, N.C.--(Business Wire)--
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company
developing a new class of drugs known as NNR Therapeutics, today announced that
J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled
to present at the Lazard Capital Markets 6th Annual Healthcare Conference at the
St. Regis Hotel in New York City on Wednesday, November 18, 2009 at 11:00 a.m.
Eastern Standard Time.
Dr. deBethizy`s presentation will be webcast and accessible from the Investor
Relations page of the Company`s website at www.targacept.com. The webcast will
also be available for replay on the Company`s website for at least two weeks
following the conference. To ensure a timely connection, it is recommended that
users register at least 15 minutes prior to the scheduled start time.
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and
develops NNR Therapeutics, a new class of drugs for the treatment of central
nervous system diseases and disorders. Targacept's product candidates
selectively modulate neuronal nicotinic receptors that serve as key regulators
of the nervous system to promote therapeutic effects and limit adverse side
effects. Targacept has clinical-stage product candidates in development for
major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer's
disease and cognitive dysfunction in schizophrenia, as well as multiple
preclinical programs. Targacept has a cognition-focused collaboration with
AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept`s news
releases are available on its website at www.targacept.com.
Targacept, Inc.
Alan Musso, 336-480-2186
VP and CFO
alan.musso@targacept.com
or
Linnden Communications
Michelle Linn, 508-362-3087
linnmich@comcast.net
Copyright Business Wire 2009
